Otsuka Announces FDA Accelerated Approval of VOYXACT® for Proteinuria Reduction in Adults with Primary IgA Nephropathy Otsuka Pharmaceutical Development & Commercialization, Inc., together with Otsuka Pharmaceutical Co., Ltd., announced that the U.S. Food and Drug Administration (FDA) has granted accelerated…
Enigma Biomedical USA Awarded $2 Million Grant from The Michael J. Fox Foundation to Advance Novel α-Synuclein PET Imaging Biomarker for Parkinson’s Disease Enigma Biomedical USA (EB USA) today announced that The Michael J. Fox Foundation for Parkinson’s Research (MJFF)…
AstraZeneca Announces $2 Billion Expansion to Strengthen Maryland Manufacturing, Advance Innovation, and Support 2,600 Jobs AstraZeneca today unveiled a major strategic investment plan totaling $2 billion to expand its long-standing manufacturing presence in Maryland, further solidifying the state’s role as…
BeOne Medicines Demonstrates Scientific Leadership in B-Cell Cancers at ASH 2025 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a rapidly expanding global oncology innovator, is set to showcase one of the most comprehensive and data-rich hematology portfolios at…
Oncolytics Biotech® Aligns with FDA on Pivotal Phase 3 Study Design for Pelareorep in First-Line Metastatic Pancreatic Cancer Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company advancing pelareorep, announced that it has reached alignment with…
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Lead Global Strategy for BOT/BAL and Early-Access Programs Agenus Inc. (Nasdaq: AGEN), a biotechnology company recognized for its long-standing leadership in immuno-oncology, announced the appointment of José Iglesias, M.D.,…
CorriXR Therapeutics Announces Publication of Preclinical Data Demonstrating the Potential of CRISPR-Directed Gene Editing to Overcome Drug Resistance in Solid Tumors CorriXR Therapeutics, Inc., an oncology-focused biotherapeutics company advancing a novel gene editing platform designed to counteract drug resistance in…
Solve Therapeutics Raises $120 Million to Accelerate Next-Generation ADC Development for Solid Tumors Solve Therapeutics, a rapidly advancing clinical-stage biotechnology company focused on creating best-in-class antibody–drug conjugates (ADCs) for the treatment of solid tumor malignancies, announced that it has secured…
JSR Life Sciences Announces Definitive Agreement to Transfer Crown Bioscience to Adicon Holdings, Marking a Significant Strategic Realignment in Oncology Research Services JSR Life Sciences LLC (“JSR Life Sciences”), a global leader in life sciences materials, bioprocessing solutions, and research…
Flightpath Biosciences Advances Precision Anti-Infective Strategy with New Drug License and Corporate Rebrand as Company Enters Next Phase of Growth Flightpath Biosciences, a clinical-stage biotechnology company committed to developing innovative treatments for infection-associated complex diseases, has announced a significant milestone…
KORU Medical Systems Reports 27% Third Quarter Revenue Growth and Raises Full-Year 2025 Guidance KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology firm dedicated to the development, manufacturing, and commercialization of patient-centric large-volume…
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business and Scientific Updates AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company dedicated to discovering and developing novel small-molecule therapeutics using its proprietary boron chemistry platform, today announced its financial…